BLRX (BioLine Rx) Beta: 1.7906 (As of Jun. 26, 2026)


BLRX BioLine Rx Ltd BLRX
23 GF Score
Price $3.07
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Beta?

BioLine Rx BLRX -2.35% 23 Beta is 1.7906 as of Jun. 26, 2026. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), BioLine Rx's Beta is 1.7906.


BioLine Rx  (NAS:BLRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioLine Rx Beta Related Terms


BioLine Rx Beta Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Beta Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.73 1.54 1.19 1.37 1.32

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.23 1.07 1.32 1.18

BLRX vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, BioLine Rx's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Beta distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Beta falls into.


BLRX
23GF Score
BioLine Rx Ltd BLRX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.7906 mean?
BioLine Rx (BLRX) has a Beta of 1.7906 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioLine Rx and its competitors.
Is BioLine Rx's Beta too high?
BioLine Rx's current Beta is 1.7906. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Beta compare to VRTX and REGN?
BioLine Rx's Beta of 1.7906 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioLine Rx and its competitors. BioLine Rx's current Beta is 1.7906. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current Beta of 1.7906. The current Beta is 1.7906. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BioLine Rx (BLRX), the current Beta is 1.7906 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:IsraelYP2:Germany
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score

Get the complete analysis for BLRX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07
Price